Recruiting
InvestigationalNo placebo
Study of ELA026 for Treatment of Secondary Hemophagocytic Lymphohistiocytosis in Patients with Lymphoma Who Have Not Received Previous Treatment
InvestigationalNo placebo
- Participants:All ages
ELA026
- 1 / 1
- trials open to patients / all trials
- 4+
- Countries
About the substance
Table of contents
- What is ELA026?
- How does ELA026 work?
- Which conditions is ELA026 studied for?
- How is ELA026 given?
- What do the clinical trials show?
- What side effects are known?
What is ELA026?
ELA026 is an investigational protein-based substance, meaning it is made from biological material rather than being a simple chemical molecule. It is being developed by Electra Therapeutics. ELA026 has no marketing authorisation in the product records, so it is not yet approved as a medicine and remains under investigation.[1] The substance is classified in the therapeutic area of immune system diseases (ATC group C20).[1] The name ELA026 is the development code used in the registry; no trade name or additional product names are listed.[1]
How does ELA026 work?
The exact mechanism of action of ELA026 is not described in the available registry data. Because it is a protein-based substance given by intravenous infusion, it belongs to the class of biological medicines, which are designed to interact with specific targets in the immune system.[1] The trial record does not state which molecular target ELA026 binds to or how it alters the course of secondary hemophagocytic lymphohistiocytosis.[1]
Which conditions is ELA026 studied for?
ELA026 is being investigated in one condition:
- Secondary hemophagocytic lymphohistiocytosis (sHLH) — a severe, life-threatening condition in which the immune system becomes overactive and attacks the body's own tissues, often triggered by an underlying disease such as lymphoma.[1]
How is ELA026 given?
ELA026 is given as an intravenous infusion, meaning it is delivered directly into a vein.[1] The pharmaceutical form listed in the registry is an infusion.[1] No dose is reported in the trial record, and the registry entry lists a dose of 0.00 mg/kg, which indicates that the dose was not specified in the register.[1]
What do the clinical trials show?
One clinical trial of ELA026 is registered in the EU Clinical Trials Information System (CTIS).[1] It is a Phase 4, interventional, open-label study with a planned enrolment of 100 participants.[1] The trial is currently authorised.[1]
What is the trial measuring?
The primary outcome is 56-day survival from the time of diagnosis.[1] This means the study will assess how many participants are still alive 56 days after their sHLH diagnosis when treated with ELA026.[1]
Who can take part in this trial?
The trial includes participants with sHLH who are treatment-naive (meaning they have not previously received treatment for the condition) and who have lymphoma as the cancer trigger.[1] This is described as Cohort A in the trial summary.[1]
What side effects are known?
The registry data provided for this trial does not report side effects of ELA026. Because ELA026 is still investigational, its safety profile is being evaluated in the ongoing clinical study.[1]
Trials with ELA026
Recruiting trials first
Quick filters